Atofab^®

Atofab^® contains the active substance atomoxetine and is used to treat attention deficit hyperactivity disorder (ADHD).

It is given to adults, adolescents and children aged 6 years and older.

Atomoxetine is used as part of a comprehensive treatment programme for this disorder, but also requires non-drug interventions such as counselling and behavioural therapy.

It is not intended for ADHD treatment in children under 6 years of age, as the efficacy and safety of the medicine in this patient group are not known.

In adults, ADHD treatment with Atofab^® is indicated if the signs of the disease are very distressing and affect the patient’s professional or social life, and if the ADHD signs were already present in childhood.